Accueil VisioCyt EN

Accroche

VisioCyt® allows an earlier diagnosis of bladder cancer from a simple urine sample. 

This innovative solution is based on a patented technology combining fluorescence imaging and artificial intelligence. 

VisioCyt® obtained the CE mark in January 2020.

Technology
Infographie
Image
Inforgraphie EN
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Image de fond
Image
banner
Clinical
Texte

The VisioCyt® 1 clinical trial started in January 2017. This trial was conducted in collboration with 14 French hospitals and included 1360 patients.

The goal is to evaluate the diagnostic perfomances of VisioCyt® in the event of a bladder tumor suspicion.

 

Image
clinique
About us
Texte

VitaDX has developed an innovative solution for the early diagnosis of bladder cancer, based on a patented technology combining image processing and artificial intelligence. VitaDX leverages research work, carried out by researchers from the Institut des Sciences Moléculaires d'Orsay (ISMO, UMR CNRS and Université Paris-Sud) and practitioners from the Kremlin Bicêtre hospital (AP-HP) whose goal was to diagnose bladder cancer earlier to optimise patient care.

 

Image
VitaDx
News
Dernières actualités
ECOSYSTEME
ECOSYSTEME - Interview of Allan Rodriguez and Dr Camélia Radulescu on B SMART
20 September 2021 - News

Thomas Hugues welcomes Allan Rodriguez (VitaDX) and Camélia Radulescu (Foch hospital) to ÉCOSYSTÈME to talk about VitaDX's new diagnostic solution…

VitaDX
4th round of financing for VitaDX
21 September 2020 - News

VitaDX completes a €3M financing round with its historical investors GO CAPITAL, ODYSSEE Venture and FFBB Management and its financial partners…

Image de fond
Image
banner
Contact
Nom commercial
VisioCyt / VitaDX International
Numéro de téléphone
(+33)143214455
74F, rue de Paris
35000 Rennes, France
28 rue de Chambéry
75015 Paris, France
Formulaire
2 + 13 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.